Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | F10 | P00742 | 5/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589241 | 0.95 | POLB (0.52) | POLBF10KLKB1KMT2AGAA | |
| SCHEMBL3580373 | 0.93 | POLB (0.55) | POLBF10KLKB1KMT2AGAA | |
| SCHEMBL3580391 | 0.89 | POLB (0.56) | POLBF10KLKB1KMT2AGAA | |
| SCHEMBL3582633 | 0.87 | POLB (0.57) | POLBF10KLKB1KMT2AMEN1 | |
| SCHEMBL3581950 | 0.86 | POLB (0.57) | POLBF10KLKB1KMT2AMEN1 | |
| SCHEMBL3588454 | 0.85 | POLB (0.54) | POLBF10KLKB1KMT2AMEN1 | |
| SCHEMBL3580419 | 0.85 | F10 (0.56) | POLBF10KLKB1KMT2AMEN1 | |
| SCHEMBL3591639 | 0.85 | F10 (0.56) | POLBF10KLKB1KMT2AMEN1 | |
| SCHEMBL3577870 | 0.84 | POLB (0.52) | POLBF10KLKB1KMT2AGAA | |
| SCHEMBL3582353 | 0.84 | POLB (0.55) | POLBF10KLKB1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732481-B2 | Prolinylarylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-08 | — | — | US | claimed |
| EP-1697318-B1 | PROLINYLARYLACETAMIDES | MERCK PATENT GMBH (DE) | 2008-08-27 | — | — | EP | claimed |
| US-20070185189-A1 | Prolinylarylacetamides | MERCK PATENT GMBH (DE) | 2007-08-09 | — | — | US | claimed |
| US-7732481-B2 | Prolinylarylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20070185189-A1 | Prolinylarylacetamides | MERCK PATENT GMBH (DE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185189-A1 | Prolinylarylacetamides | F12, F11, F2 | POLB 3435/4885F10 5/4885KLKB1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.